The DOI matches its OpenAlex record.
Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment
Abstract
This article synthesizes the evidence on the cost-effectiveness of renal replacement therapy and discusses the findings in light of the frequent practice of using the cost-effectiveness of hemodialysis as a benchmark of societal willingness to pay. The authors conducted a meta-analytic review of the medical and economic literature for economic evaluations of hemodialysis, peritoneal dialysis, and kidney transplantation. Cost-effectiveness ratios were translated into 2000 U.S. dollars per life-year (LY) saved. Thirteen studies published between 1968 and 1998 provided such information. The cost effectiveness of center hemodialysis remained within a narrow range of $55,000 to $80,000/LY in most studies despite considerable variation in methodology and imputed costs. The cost-effectiveness of home hemodialysis was found to be between $33,000 and $50,000/LY. Kidney transplantation, however, has become more cost-effective over time, approaching $10,000/LY. Estimates of the cost per life-year gained from hemodialysis have been remarkably stable over the past 3 decades, after adjusting for price levels. Uses of the cost-effectiveness ratio of $55,000/LY for center hemodialysis as a lower boundary of society's willingness to pay for an additional life-year can be supported under certain assumptions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The current and future landscape of dialysis
Himmelfarb, J., Vanholder, R., Mehrotra, R., & Tonelli, M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0315-4 · Cited by 650
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Reynolds, M. R., Magnuson, E. A., Wang, K., Lei, Y., Vilain, K., Walczak, J., Kodali, S. K., Lasala, J. M., O'Neill, W. W., Davidson, C. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.054072 · Cited by 294
Economic evaluation of dialysis therapies
Klarenbach, S. W., Tonelli, M., Chui, B., & Manns, B. J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.145 · Cited by 260
Metadata
- Authors
- Winkelmayer, W. C., Weinstein, M. C., Mittleman, M. A., Glynn, R. J., & Pliskin, J. S.
- Venue
- Medical Decision Making
- Publisher
- SAGE Publishing
- Published
- 2002-10-01
- Volume
- 22
- Issue
- 5
- Pages
- 417-430
- ISSN
- 0272-989X (ISSN-L)
- OpenAlex
- W2146114745
- Cited by
- 341
- References
- 0
- FWCI
- 39.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment. https://app.cochat.ai/papers/10.1177/027298902236927
- The paper
- Winkelmayer, W. C., Weinstein, M. C., Mittleman, M. A., Glynn, R. J., & Pliskin, J. S. (2002). Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment. Medical Decision Making. https://doi.org/10.1177/027298902236927
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.